ACR Appropriateness Criteria s Radiation Therapy for Small-Cell Lung Cancer

: The current standard of care for small cell lung cancer is combined-modality therapy, including the use of chemotherapy, surgery (in selected cases of limited stage of disease), and radiation therapy. This review will focus on the role, dose fractionation, technology and timing of thoracic radiation, and the role and dose regimen of prophylactic cranial irradiation for both limited and extensive stage of diseases. Consensus recommendation from experts is summarized in the tables for 2 typical case scenarios. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

[1]  Zuofeng Li,et al.  Improving the Therapeutic Ratio by Using Proton Therapy in Patients With Stage I or II Seminoma , 2013, American journal of clinical oncology.

[2]  P. Lambin,et al.  Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. , 2010, International journal of radiation oncology, biology, physics.

[3]  R. Arriagada,et al.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. , 2009, The Lancet. Oncology.

[4]  Charles R. Thomas,et al.  Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. , 2009, Lung cancer.

[5]  Andrew Bottomley,et al.  Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Jeremic,et al.  Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). , 2008, International journal of radiation oncology, biology, physics.

[7]  L. Collette,et al.  Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.

[8]  E. Vokes,et al.  Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002 , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  A. Hackshaw,et al.  Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Curran,et al.  Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241. , 2006, Journal of Clinical Oncology.

[11]  N. Hanna,et al.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Lambin,et al.  Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Willers,et al.  Introduction to clinical radiation biology. , 2006, Hematology/oncology clinics of North America.

[14]  N. Saijo,et al.  Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702 , 2005 .

[15]  R. Marks,et al.  Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Herbst,et al.  Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. , 2005, Clinical lung cancer.

[17]  M. Socinski,et al.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jeffrey D Bradley,et al.  Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Arusell,et al.  Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[20]  J. Herndon,et al.  70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. , 2004, International journal of radiation oncology, biology, physics.

[21]  P. Lambin,et al.  Early versus late chest radiotherapy for limited stage small cell lung cancer. , 2004, The Cochrane database of systematic reviews.

[22]  N. Choi,et al.  Radiation dose escalation in limited-stage small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.

[23]  D. Ettinger,et al.  Radiotherapy patterns of care study in lung carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Clough,et al.  Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.

[25]  J. Sørensen The role of prophylactic brain irradiation in small cell lung cancer treatment. , 2003, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[26]  P. Jänne,et al.  Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America , 2002, Cancer.

[27]  N. Saijo,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[29]  L. Stitt,et al.  Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. , 2001, Lung cancer.

[30]  D. Cella,et al.  Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  V. Georgoulias,et al.  A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  E. Lemarié,et al.  Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. , 2001, Journal of the National Cancer Institute.

[33]  H. Niell Extensive stage small cell lung cancer , 2001, Current treatment options in oncology.

[34]  J. Jett,et al.  Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[36]  B. Jeremic,et al.  Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[38]  A. Coldman,et al.  Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Herndon,et al.  Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Sotiriou,et al.  Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. , 1998, Lung cancer.

[41]  O. S. Nielsen,et al.  Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Giaccone,et al.  Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Souhami,et al.  Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. , 1997, Journal of the National Cancer Institute.

[44]  B. Jeremic,et al.  Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Girling Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial , 1996, The Lancet.

[46]  L. Einhorn,et al.  Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P Chomy,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. , 1995, Journal of the National Cancer Institute.

[48]  D. Payne,et al.  Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J P Pignon,et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.

[50]  P. Warde,et al.  Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[52]  J. Ware,et al.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. , 1987, The New England journal of medicine.

[53]  D. Osoba,et al.  VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Cox,et al.  What is the lowest effective biologic dose for prophylactic cranial irradiation? , 1985, American journal of clinical oncology.

[55]  A. Bartolucci,et al.  The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma , 1979, Cancer.

[56]  R. Makuch,et al.  Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. , 1979, Cancer treatment reports.

[57]  W. H. Bond,et al.  Long-term results in combined-modality treatment of small cell carcinoma of the lung. , 1978, Seminars in oncology.

[58]  R. Weiss Small-cell carcinoma of the lung: therapeutic management. , 1978, Annals of internal medicine.

[59]  W. Fox,et al.  Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. , 1973, Lancet.

[60]  M. Zelen Keynote address on biostatistics and data retrieval. , 1973, Cancer chemotherapy reports. Part 3.

[61]  A. Miller,et al.  Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. , 1969, Lancet.

[62]  R. A. Green,et al.  Alkylating agents in bronchogenic carcinoma. , 1969, The American journal of medicine.